Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension

Hypertension Research

Volumn 34, Issue 4, 2011, Pages 484-488

  Stumpf, Christian ^a   Auer, Christoph ^a   Yilmaz, Atilla ^b   Lewczuk, Piotr ^a   Klinghammer, Lutz ^a   Schneider, Markus ^a   Daniel, Werner G ^a   Schmieder, Roland E ^a   Garlichs, Christoph D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

cytokines; inflammation; IP 10; microalbuminuria; T cells

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 7;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; INFLAMMATION; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; SYSTOLIC BLOOD PRESSURE; TH1 CELL;

CASE-CONTROL STUDIES; CHEMOKINE CXCL10; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-7; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; T-LYMPHOCYTES;

EID: 79953674514     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.258     Document Type: Article

References (31)

1. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951. (Pubitemid 37505526)
2. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861. (Pubitemid 32436948)
3. Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, Daniel WG, Garlichs CD. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005; 23: 995-1000. (Pubitemid 40637918)
4. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511. (Pubitemid 36158056)
5. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-II10. (Pubitemid 38724149)
6. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-2460. (Pubitemid 47529329)
7. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969.
8. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194-199. (Pubitemid 43732249)
9. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O, Kasuga A, Saruta T, Narumi S. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001; 24: 510-515. (Pubitemid 32198422)
10. Suzuki R, Shimada A, Maruyama T, Funae O, Morimoto J, Kodama K, Oikawa Y, Kasuga A, Matsubara K, Saruta T, Narumi S. T-cell function in anti-GAD65(+)diabetes with residual beta-cell function. J Autoimmun 2003; 20: 83-90. (Pubitemid 36207630)
11. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-3204. (Pubitemid 34256349)
12. Frangogiannis NG, Mendoza LH, Lewallen M, Michael LH, Smith CW, Entman ML. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FA S E B J 2001; 15: 1428-1430.
13. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-198. (Pubitemid 32245668)
14. Nicoletti F, Conget I, Di Mauro M, Di Marco R, Mazzarino MC, Bendtzen K, Messina A, Gomis R. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/ CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45: 1107-1110. (Pubitemid 34985286)
15. Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G, Scarlato G. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002; 195: 41-46. (Pubitemid 34175097)
16. Tang NL, Chan PK, Wong CK, To KF, Wu AK, Sung YM, Hui DS, Sung JJ, Lam CW. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 2005; 51: 2333-2340. (Pubitemid 41692578)
17. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97: 748-754. (Pubitemid 46779960)
18. Svendsen UG. Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand A 1976; 84: 523-528.
19. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension 2006; 48: 149-156. (Pubitemid 44297537)
20. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 2007; 293: F616-F623. (Pubitemid 47358134)
21. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 2006; 17: S218-S225. (Pubitemid 44865252)
22. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8: 207-219. (Pubitemid 28077928)
23. Shigihara T, Oikawa Y, Kanazawa Y, Okubo Y, Narumi S, Saruta T, Shimada A. Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun 2006; 26: 66-71. (Pubitemid 43138895)
24. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008; 295: F515-F524.
25. Kramer S, Binder E, Loof T, Wang-Rosenke Y, Martini S, Khadzhynov D, Budde K, Neumayer HH, Peters H. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Am J Physiol Renal Physiol 2009; 297: F218-F227.
26. Tamaru M, Nishioji K, Kobayashi Y, Watanabe Y, Itoh Y, Okanoue T, Murai M, Matsushima K, Narumi S. Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10. Cytokine 2000; 12: 299-308. (Pubitemid 30449819)
27. Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci 2008; 13: 944-955. (Pubitemid 351594739)
28. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P, Craddock C, Moss PA. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007; 110: 3827-3832. (Pubitemid 350248437)
29. Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B, Sugamura K, Wunderli-Allenspach H, Moser R. Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 1996; 87: 4286-4295. (Pubitemid 26152270)
30. Faffe DS, Flynt L, Bourgeois K, Panettieri Jr RA, Shore SA. Interleukin-13 and interleukin-4 induce vascular endothelial growth factor release from airway smooth muscle cells: role of vascular endothelial growth factor genotype. Am J Respir Cell Mol Biol 2006; 34: 213-218. (Pubitemid 43202468)
31. Stumpf C, Jukic J, Yilmaz A, Raaz D, Schmieder RE, Daniel WG, Garlichs CD. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur J Clin Invest 2009; 39: 31-36.